# Safety and Antidepressant Effects of Rellidep in Major Depressive Disorder

> **NCT00446719** · PHASE2,PHASE3 · COMPLETED · sponsor: **Mount Sinai Hospital, Canada** · enrollment: 23 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** Rellidep

## Key facts

- **NCT ID:** NCT00446719
- **Lead sponsor:** Mount Sinai Hospital, Canada
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2011-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00446719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00446719, "Safety and Antidepressant Effects of Rellidep in Major Depressive Disorder". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00446719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*